Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AD109

Small molecule · developed by Apnimed

Phase 3 Most advanced trial (none active)

APMD Developer

2 Registered trials

What is AD109?

AD109 is an oral tablet combining aroxybutynin and atomoxetine, taken once daily at bedtime.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Respiratory
Developer: Apnimed (APMD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05813275	Phase 3	OSA	Completed	APMD
NCT04631107	Phase 2	Obstructive Sleep Apnea	Completed	APMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obstructive Sleep ApneaOSA

More from Apnimed

AD036 Phase 2 AD113 Phase 2 AD182 Phase 2 AD313 Phase 1/2 AD504 Phase 2 Aroxybutynin and Atomoxetine Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the APMD page.

Follow APMD, the company behind AD109

See APMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APMD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z